MUMBAI, India, June 20, 2020 /PRNewswire/ -- Piramal Enterprises Limited's (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that the Company has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary pre-closing conditions. According to the terms of the agreement, PEL, through one of its Affiliates, would acquire at closing a 100% stake in the entity that operates the facility and owns the related real estate.
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 21 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Cosette Pharmaceuticals, a generic pharmaceutical company primarily focused on extended topical and suppository products, has purchased G&W Laboratories' finished dosage manufacturing plant located in Lincolnton, NC.
Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.
G AND W LABS INC`s generic FLUOXETINE HYDROCHLORIDE Receives Approval in US
G&W Labs` Generic Lidocaine Receives Approval in US
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Amneal’s $1.45 billion acquisition of an equity share in Impax likely would be anticompetitive.
G And W Lab’s Generic Triamcinolone Acetonide Receives Approval In US
G And W Lab’s Generic Nystatin Approval In US
Enforcement Report - Week of July 12, 2017